- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06176222
Combined Use of Naldebain® ER Injection and Precedex® After VATS
To Investigate the Effects of Combined Use of Naldebain® ER Injection and Precedex® After Video-assisted Thoracoscopic Surgery
The goal of this clinical trial is to investigate the effects of combined use of Naldebain® ER Injection and Precedex® in patients received video-assisted thoracoscopic surgery. The main questions it aims to answer are:
- the pain intensity after surgery
- the level of dizziness after surgery Participants will receice ultrasound-guided thoracic paravertebral nerve block, intramuscular Naldebain® ER injection and intravenous Precedex® infusion.
If there is a comparison group: Researchers will compare experimental group with placebo group to see if pain and dizziness after surgery can reduced.
Study Overview
Status
Intervention / Treatment
Detailed Description
Ⅰ.Protocol title: To investigate the effects of combined use of Naldebain® ER Injection and Precedex® after video-assisted thoracoscopic surgery
Ⅱ.Objectives: Video-assisted thoracoscopic surgery (VATS) is currently the mainstream of thoracic surgery, but it may also cause stronger postoperative pain than expected. Therefore, pain control after thoracoscopic surgery is very important, because increased acute pain will increase the incidence of chronic pain, and untreated pain may lead to increased postoperative complications. At present, the combined use of regional nerve block, opioids, and non-steroidal anti-inflammatory drugs is the current mainstream strategy for multimodal analgesia after thoracoscopic surgery.
Paravertebral block (PVB) involves injecting a local anesthetic into the paravertebral wedge-shaped space as it emerges from the intervertebral foramen. It produces an ipsilateral somatosensory and sympathetic block, and has good analgesic effects on anesthesia and unilaterally induced pain from the chest and abdomen. So far, thoracic paravertebral block (TPVB) is considered the best alternative to thoracic epidural analgesia because it can provide effective immediate postoperative analgesic effect in patients undergoing VATS.
Naldebain® ER Injection is a long-acting prodrug of Nalbuphine, aimed at addressing the medical need for long-acting analgesics. It is an agonist-antagonist of synthetic phenanthrene series opioids. It is chemically related to the widely used opioid antagonist naloxone and the potent opioid pain reliever oxymorphone. At present, nalbuphine sebacate has been used in many surgical procedures to relieve postoperative pain.
Precedex® injection (dexmedetomidine hydrochloride), a centrally acting α2-receptor agonist, has the same sedative effects as other benzodiazepine drugs. However, due to the different pharmacological mechanisms, there are no side effects such as respiratory depression and delirium. In addition, according to Venn et al. in 2000, when 33 postoperative patients were using respirators in the intensive care unit, they found that the use of dexmedetomidine could reduce the use of morphine by 50%, thereby reducing the possible side effects of opioids and as a good adjuvant drug for pain relief.
In view of the fact that patients undergo thoracoscopic surgery, good analgesic function is crucial for the recovery of postoperative pulmonary function. Therefore, the purpose of this study is to investigate the application effect of the multimodal analgesic formula combined with thoracic paravertebral nerve block, Naldebain® ER Injection and Precedex® injection after VATS.
III. Study design 1. ☑ Control: ☑ placebo
active (please specify name and dosage)
- others
- Uncontrolled 2. Blinding: □ open-label □ single blind ☑ double blind □ others 3. Randomized: ☑ yes □ no 4. ☑ Parallel □ cross-over □ others 5. Duration of study:from IRB approval ~to 2025 , 12 , 31 ,total 24 months Duration of Enrollment : from IRB approval ~to 2025 , 12 , 31 ,total 24 months Duration of treatment:from IRB approval ~to 2025 , 12, 31 ,total 24 months Duration of follow-up: from IRB approval ~to 2025 , 12 , 31 ,total 24 months
- Multi-national □multi-center(Taiwan) ☑single center(Taiwan) 6. Number of subjects: 70 7. Is there any of the followings included DSMB, Data Safety Monitoring Board:
yes ☑ no IV. Assessment criteria
Efficacy:
It can effectively reduce the expected moderate and severe acute pain after surgery, and reduce the degree and incidence of side effects of analgesic drugs.
Safety:
Side Effects: Hypotension, hypertension, nausea, bradycardia, fever, vomiting, tissue hypoxia, tachycardia, and anemia.
Contraindications: Dexmedetomidine Hydrochloride is contraindicated in patients who are known to be allergic to the components of Dexmedetomidine.
Precautions: 1. For patients with severe heart block and/or severe ventricular insufficiency, it should be used with caution. Since Precedex reduces the activity of sympathetic nerves, it can be expected that the effect of hypotension and/or bradycardia may be more pronounced in patients with low blood volume, diabetes or chronic hypertension, and elderly patients. 2. When it is necessary to use other vasodilators or drugs that lower the heart rate (negative chronotropic agents), administering Precedex at the same time may have a drug effect and should be used with caution.
Overdose: Discontinue immediately. Oxygen, intravenous drips, vasoconstrictors, and other supportive therapies may be used as needed.
V. Selection criteria
- Main inclusion criteria:
- Subject's age: 20~65 years old
- ASA classification: I~III
- Patients who need postoperative pain relief due to thoracoscopic surgery 2. Main exclusion criteria: 1. The patient suffers from a communication disorder 2. The patient has coagulopathy 3. Sick with obvious heart, lung, liver or kidney disease 4. The patient's body mass index is less than 18.5 or greater than 35 5. Pregnant patients 6. Patients who took opioids for more than three weeks before surgery 7. Patients with contraindications to local anesthesia 8. Patients with a history of chronic pain 9. Patients with a history of drug allergy to Naldebain® ER Injection, COX2-inhibitor NSAIDs (such as parecoxib), or Precedex® VI. Statistical analysis
- Statistical Method for Efficacy / Safety measurements:
The basic characteristics of the two groups of patients are presented with descriptive statistics. All results are expressed as mean ± standard deviation (SD) or applicable percentage. The differences between the groups were analyzed using ANOVA (one-way analysis of variance), and then paired comparisons were made with the post-event Student-Newman-Keuls-Test. The classified data is analyzed using X2 or Fisher's exact test. P value less than 0.05 is considered to be a significant difference.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Hung-Te Hsu, MD, PhD
- Phone Number: 7033 +88673121101
- Email: hdhsu1228@hotmail.com
Study Locations
-
-
-
Kaohsiung City, Taiwan, 833
- Hung-Te Hsu
-
Contact:
- Hung-Te Hsu, MD, PhD
- Phone Number: 7033 +88673121101
- Email: hdhsu1228@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject's age: 18~65 years old
- ASA classification: I~III Exclusion Criteria:
- Patients who need postoperative pain relief due to thoracoscopic surgery
Exclusion Criteria:
- The patient suffers from a communication disorder
- The patient has coagulopathy
- Sick with obvious heart, lung, liver or kidney disease
- The patient's body mass index is less than 18.5 or greater than 35
- Pregnant patients
- Patients who took opioids for more than three weeks before surgery
- Patients with contraindications to local anesthesia
- Patients with a history of chronic pain
- Patients with a history of drug allergy to Naldebain® ER Injection, COX2-inhibitor NSAIDs (such as parecoxib), or Precedex®
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Precedex Group
Drug: PRECEDEX INJ★ 2ML Dosage form: 100 mcg/ml dexmedetomidine Dosage: 0.1~0.4
mcg/kg/hr intravenous infusion Frequency and Duration: intrvenous infusion 12 hours after the surgery immediately
|
patient received PRECEDEX INJ★ 2ML 0.1~0.4
mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
Other Names:
|
Placebo Comparator: Placebo Group
Drug: 0.9% Normal Sline Dosage: 0.1 ml/kg/hr intravenous infusion Frequency and Duration: intrvenous infusion 12 hours after the surgery immediately
|
patient received Normal Saline 0.1 ml/kg/hr intravenous infusion 12 hours after the surgery immediately
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
poatoperative analgesic effect
Time Frame: During the 60 minutes of rest in the PACU, the patient's pain intensity was assessed every fifteen minutes.
|
Use the numerical rating scale (NRS) score to ass the intensity of pain after surgery
|
During the 60 minutes of rest in the PACU, the patient's pain intensity was assessed every fifteen minutes.
|
poatoperative analgesic effect
Time Frame: the first morning and afternoon after surgery, and the second morning and afternoon after surgery
|
Use the numerical rating scale (NRS) score to ass the intensity of pain after surgery
|
the first morning and afternoon after surgery, and the second morning and afternoon after surgery
|
poatoperative analgesic effect
Time Frame: the third day after surgery, the fourth day after surgery, the fifth day after surgery, and the sixth day after surgery
|
Use the numerical rating scale (NRS) score to ass the intensity of pain after surgery
|
the third day after surgery, the fourth day after surgery, the fifth day after surgery, and the sixth day after surgery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hung-Te Hsu, MD, PhD, Department of Anesthesiology, Kaohsiung Medical University Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Postoperative Complications
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- KMUHIRB-F(I)-20230150
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Complications
-
Marmara UniversityHacettepe University; Cukurova University; Gazi University; Baskent University; Istanbul... and other collaboratorsNot yet recruitingComplications, PostoperativeTurkey
-
Syed HusainRecruitingComplications, PostoperativeUnited States
-
Vastra Gotaland RegionRecruitingSurgery | Lung Infection | Complications, PostoperativeSweden
-
University of PittsburghCompletedLiver Transplant; Complications | Perioperative/Postoperative ComplicationsUnited States
-
Washington University School of MedicineNational Institute of Nursing Research (NINR)CompletedSurgery | Surgery--Complications | Perioperative/Postoperative ComplicationsUnited States
-
Wake Forest University Health SciencesTerminatedPerioperative/Postoperative ComplicationsUnited States
-
Technical University of MunichHealth Information Management, BelgiumActive, not recruitingPerioperative/Postoperative Complications
-
Atatürk Chest Diseases and Chest Surgery Training...CompletedPerioperative/Postoperative ComplicationsTurkey
-
Namigar TurgutCompletedPerioperative/Postoperative ComplicationsTurkey
-
TC Erciyes UniversityCompletedPerioperative/Postoperative ComplicationsTurkey
Clinical Trials on PRECEDEX INJ★ 2ML
-
Yooyoung Pharmaceutical Co., Ltd.CompletedOsteoarthritis, KneeKorea, Republic of
-
Ajou University School of MedicineIlsung Pharmaceuticals CO.,LTD.CompletedSpinal Anesthesia | Autonomic Nervous SystemKorea, Republic of
-
Paolo GoffredoUnknown
-
Zagazig UniversityCompletedAnesthesia Intubation ComplicationEgypt
-
National Cardiovascular Center Harapan Kita Hospital...CompletedTetralogy of Fallot | Cardiopulmonary Bypass | Congenital Heart Disease in ChildrenIndonesia
-
Baskent UniversityCompletedHip Fracture | Chronic Renal FailureTurkey